Specificity of Aptamers U2 and Gol1 to EGFR-Positive Human Glioblastoma Cells in Vitro-Reference-Cited by-同舟云学术

Specificity of Aptamers U2 and Gol1 to EGFR-Positive Human Glioblastoma Cells in Vitro

Published:2024-07 Issue:6 Volume:54 Page:912-922
ISSN:0097-0549
Container-title:Neuroscience and Behavioral Physiology
language:en
Short-container-title:Neurosci Behav Physi

Author:

Dzarieva F. M.,Shamadykova D. V.,Sluchanko O. V.,Pavlova S. A.,Fab L. V.,Ryabova A. V.,Panteleev D. Yu.,Kopylov A. M.,Usachev D. Yu.,Golovin A. V.,Pavlova G. V.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11055-024-01676-w.pdf

Reference40 articles.

1. Babic, I., Anderson, E. S., Tanaka, K., et al., “EGFR mutation-induced alternative splicing of max contributes to growth of glycolytic tumors in brain cancer,” Cell Metab., 17, No. 6, 1000–1008 (2013), https://doi.org/10.1016/j.cmet.2013.04.013.

2. Brand, T. M., Iida, M., Luthar, N., et al., “Nuclear EGFR as a molecular target in cancer,” Radiother. Oncol., 108, No. 3, 370–377 (2013), https://doi.org/10.1016/j.radonc.2013.06.010.

3. Ciznadija, D., Liu, Y., Pyonteck, S. M., et al., “Cyclin D1 and Cdk4 mediate development of neurologically destructive oligodendroglioma,” Cancer Res., 71, No. 19, 6174–6183 (2011), https://doi.org/10.1158/0008-5472.CAN-11-1031.

4. Cooper, A. J., Sequist, L. V., and Lin, J. J., “Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management,” Nat. Rev. Clin. Oncol., 19, No. 8, 499–514 (2022), https://doi.org/10.1038/s41571-022-00639-9.

5. Cvrljevic, A. N., Akhavan, D., Wu, M., et al., “Activation of Src induces mitochondrial localisation of de2–7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism,” J. Cell Sci., 124, No. 17, 2938–2950 (2011), https://doi.org/10.1242/jcs.083295.